NASDAQ:RNA

Avidity Biosciences Q1 2026 Earnings Results & Report

Avidity Biosciences logo
$6.43 -1.08 (-14.38%)
As of 04:00 PM Eastern

Avidity Biosciences beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.97 versus the -$1.05 consensus estimate, while revenue of $19.64 million topped the $2 million estimate by $17.64 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Avidity Biosciences EPS Results

Actual EPS
-$0.97
Consensus EPS
-$1.05
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Avidity Biosciences Revenue Results

Actual Revenue
$19.64 million
Expected Revenue
$2 million
Beat/Miss
Beat by +$17.64 million
YoY Revenue Growth
N/A

Avidity Biosciences Q1 2026 Earnings FAQ

Avidity Biosciences (NASDAQ:RNA) reported earnings of -$0.97 per share for Q1 2026, beating the consensus estimate of -$1.05. The report was announced on Thursday, May 14, 2026.

Avidity Biosciences reported revenue of $19.64 million for Q1 2026, against a consensus estimate of $2 million.

Avidity Biosciences Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Avidity Biosciences (RNA) Expected to Post Earnings on Thursday
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells.

The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

View Avidity Biosciences Profile